Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance

Publication Name: Breast Cancer Research and Treatment

Author(s): Valesca P. Retel, Manuela A. Joore, Wim H. van Harten

Both the 70-gene signature and the 21-gene assay are novel prognostic tests used to guide adjuvant chemotherapy decisions in patients with early breast cancer. Although the results of ongoing prospective trials will only become available in some years, the tests … Continued

First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations

Publication Name: Breast Cancer Res Treat

Author(s): Takayuki Iwamoto, Ju-Seog Lee. Giampaolo Bianchini, Rebekah E. Hubbard

The aims of this study were to compare the performance of six different genomic prognostic markers to predict long-term survival and chemotherapy response on the same patient cohort and assess if clinicopathological variables carry independent prognostic and predictive values. We … Continued

A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response

Publication Name: Breast Cancer Research and Treatment

Author(s): Oscar Krijgsman, Paul Roepman, Wilbert Zwart, Jason S. Carroll, Sun Tian, Femke A. de Snoo, Richard A. Bender, Rene Bernards, Annuska M. Glas

Classification of breast cancer into molecular subtypes maybe important for the proper selection of therapy, as tumors with seemingly similar histopathological features can have strikingly different clinical outcomes. Herein, we report the development of a molecular subtyping profile (BluePrint), that … Continued

Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

Publication Name: Annals of Oncology

Author(s): A. Goldhirsch, W. C. Wood, A. S. Coates, R. D. Gelber, B. Thu¨ rlimann, H.-J. Senn & Panel

The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach to the classification of patients for therapeutic purposes based on the recognition of intrinsic biological subtypes within the breast cancer spectrum. For practical purposes, these … Continued

Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue Are Largely Comparable to Fresh Frozen Matched Tissue

Publication Name: PLOS ONE

Author(s): Lorenza Mittempergher, Jorma J. de Ronde, Marja Nieuwland, Ron M. Kerkhoven, Iris Simon,Emiel J. Th. Rutgers, Lodewyk F. A. Wessels, Laura J. Van't Veer

Background and Methods: Formalin Fixed Paraffin Embedded (FFPE) samples represent a valuable resource for cancer research. However, the discovery and development of new cancer biomarkers often requires fresh frozen (FF) samples. Recently, the Whole Genome (WG) DASL (cDNA-mediated Annealing, Selection, … Continued

TSPYL5 suppresses p53 levels and function by physical interaction with USP7

Publication Name: Nature Cell Biology

Author(s): Mirjam T. Epping, Lars A.T. Meijer, Oscar Krijgsman, Johannes L. Bos, Pier Paolo Pandolfi and René Bernards

We have previously reported a gene expression signature that is a powerful predictor of poor clinical outcome in breast cancer1. Among the seventy genes in this expression profile is a gene of unknown function: TSPYL5 (TSPY-like 5, also known as … Continued

Cost-Effectiveness of 70-Gene MammaPrint Signature in Node-Negative Breast Cancer

Publication Name: The American Journal of Managed Care

Author(s): Er Chen, MPP; Kuo Bianchini Tong, MS; and Jennifer L. Malin, MD, PhD

Objective: To evaluate the cost-effectiveness of 70-gene MammaPrint signature (Agendia Inc, Huntington Beach, CA) vs Adjuvant! Online soft ware (AS) (http://www.adjuvantonline.com) in patients 60 years or younger with early-stage breast cancer. Study Design: Cost-effectiveness and cost-utility analyses from a US … Continued

Biological Functions of the Genes in the Mammaprint Breast Cancer Profile Reflect the Hallmarks of Cancer

Publication Name: Biomarker Insights

Author(s): Sun Tian, Paul Roepman, Laura J van’t Veer, Rene Bernards, Femke de Snoo, and Annuska M Glas

Background: MammaPrint was developed as a diagnostic tool to predict risk of breast cancer metastasis using the expression of 70 genes. To better understand the tumor biology assessed by MammaPrint, we interpreted the biological functions of the 70-genes and showed … Continued

Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer

Publication Name: Journal of Clinical Oncology

Author(s): Ramon Salazar, Paul Roepman, Gabriel Capella, Victor Moreno, Iris Simon, Christa Dreezen, Adriana Lopez-Doriga, Cristina Santos, Corrie Marijnen, Johan Westerga, Sjoerd Bruin, David Kerr, Peter Kuppen, Cornelis van de Velde, Hans Morreau, Loes Van Velthuy

Purpose: This study aims to develop a robust gene expression classifier that can predict disease relapse in patients with early-stage colorectal cancer (CRC). Patients and Methods Fresh frozen tumor tissue from 188 patients with stage I to IV CRC undergoing … Continued

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature

Publication Name: British Journal of Cancer

Author(s): M Knauer, F Cardoso, J Wesseling, PL Bedard, SC Linn, EJT Rutgers, and LJ van 't Veer

BACKGROUND: Overexpression of HER-2 is observed in 15–25% of breast cancers, and is associated with increased risk of recurrence. Current guidelines recommend trastuzumab and chemotherapy for most HER-2-positive patients. However, the majority of patients does not recur and might thus … Continued